Alembic Pharma Jumps 12% On USFDA Nod For Cancer Drug; SEBI RA Spots Bullish Breakout
Synopsis
Alembic Pharma’s latest chart signals indicate rising momentum, with the analyst pointing to a breakout and a bullish RSI crossover on both the daily and weekly timeframes.
Alembic Pharmaceuticals jumped more than 12% after receiving approval from the U.S. Food and Drug Administration (USFDA) for its generic version of Doxorubicin Hydrochloride Liposome injection.
The drug, used in cancer treatment, falls under a high-value, competitive segment in the U.S. pharmaceutical market.
The clearance is another step in Alembic’s efforts to expand its U.S. generics portfolio.
SEBI-registered research analyst Sunil Kotak said the daily chart for Alembic Pharma reflected a bullish setup.
He noted that both price action and volume are positive, with a breakout visible on the charts.
According to Kotak, the Relative Strength Index (RSI) has crossed above 60 on both daily and weekly charts, signalling positive momentum.
He identified a strong demand zone between ₹1,040 and ₹1,060, and a supply zone between ₹1,160 and ₹1,180.
“The charts are bullish,” Kotak said.
On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.
The stock has risen 3.6% so far in 2025.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.